Brief: Faes Farma Sees 2030 Revenues Of Around 1 Bln Euros
22/04/2025 10:57
April 22 (Reuters) - Faes Farma SA FAE.MC: SEES 2025-2030 AVERAGE CAPEX OF BETWEEN 20 AND 25 MILLION EUROS COMMITTED TO INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT AND INNOVATION FROM 6% TO 10% OF PHARMACEUTICAL SALES BY 2030 IN SHORT TO MEDIUM TERM, THERAPEUTIC DIVERSIFICATION WILL BE STRENGTHENED THROUGH M&A ACTIVITY INCREMENTAL INNOVATION OF THREE MAIN MOLECULES IN PORTFOLIO TO CONTRIBUTE AROUND 35% OF 2030 REVENUES OF THESE SEES REVENUE ORGANIC GROWTH OF +8/10% IN 2025, DRIVEN BY STRONG INTERNATIONAL SALES PERFORMANCE IN PHARMA (EXCLUDING EDOL) SEES REVENUE CAGR 2024-30 AT +11-12% INCLUDING M&A, OF WHICH +8-9% CORRESPONDS TO ORGANIC GROWTH LED BY LATAM AND GULF EBITDA IS EXPECTED TO BE -6/-9% IN 2025, IMPACTED BY BILASTINE LICENCES IN JAPAN AND CANADA AND DERIO ONE-OFF SEES 2030 REVENUES OF AROUND 1.00 BILLION EUROS SEES 2030 EBITDA, INCLUDING M&A, AT ABOUT 240 MILLION EUROS SEES ADJUSTED EBITDA IN 2025 AT +3/5% WITHOUT DERIO ONE-OFF Source text: ID:nCNMw4bDPF Further company coverage: FAE.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))